

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number  
**WO 01/72848 A1**

(51) International Patent Classification<sup>7</sup>: **C08B 37/10.**  
37/00. A61K 31/715

(21) International Application Number: PCT/EP01/03461

(22) International Filing Date: 27 March 2001 (27.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
MI2000A000665 30 March 2000 (30.03.2000) IT

(71) Applicant (*for all designated States except US*): **INALCO**  
S.P.A. [IT/IT]; Via Calabiana, 18, I-20139 Milano (IT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ZOPPETTI, Giorgio** [IT/IT]; Via Mac Mahon, 43, I-20155 Milano (IT).  
**ORESTE, Pasqua** [IT/IT]; Via Mac Mahon, 43, I-20155 Milano (IT). **CIPOLLETTI, Giovanni** [IT/IT]; Via Tagliamento, 21, I-20139 Milano (IT).

(74) Agent: **GERVASI, Gemma**; Notarbartolo & Gervasi  
S.p.A., Corso di Porta Vittoria, 9, I-20122 Milano (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: GLYCOSAMINOGLYCANS DERIVED FROM THE K5 POLYSACCHARIDE HAVING HIGH ANTICOAGULANT AND ANTITHROMBOTIC ACTIVITY AND PROCESS FOR THEIR PREPARATION

(57) Abstract: Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity obtained by a process comprising the preparation of the K5 polysaccharide from *Escherichia coli*, N-deacetylation/N-sulfation, C-5 epimerization, supersulfation, selective O-desulfation, selective 6-O sulfation and N-sulfation, wherein said epimerization is carried out using the glucuronosyl C-5 epimerase enzyme in solution or in immobilized form in presence of specific divalent cations.

WO 01/72848 A1

# GLYCOSAMINOGLYCANS DERIVED FROM THE K5 POLYSACCHARIDE HAVING HIGH ANTICOAGULANT AND ANTITHROMBOTIC ACTIVITY AND PROCESS FOR THEIR PREPARATION

## PRIOR ART

The glycosaminoglycans are biopolymers industrially extracted from different animal organs such as the intestinal mucosa, the lung etc.

According to their structure, the glycosaminoglycans are divided in heparin, heparan sulfate, dermatan sulfate, chondroitin sulfate and ialuronic acid. In particular heparin and heparan sulfate are composed of repeating disaccharide units consisting of an uronic acid (L-iduronic or D-glucuronic) and an amino sugar (glucosamine).

The uronic acid may be sulfated in position 2 and the glucosamine may be mostly N-acetylated (heparan sulfate) or N-sulfated (heparin) and 6-O sulfated. Moreover the glucosamine may also contain a sulfate group in position 3.

Heparin and heparan sulfate are polydispersed molecules having a molecular weight ranging from 3,000 to 30,000 D.

Beside the known anticoagulant and antithrombotic activity, to heparin an antilipemic, antiproliferative, antiviral, antitumor and antiangiogenetic activity is also recognized. In order to satisfy the greater request of raw material for these new therapeutic areas a new productive way alternative to the extraction from animal tissues is needed. The natural biosynthesis of heparin in mammals and its properties have been described by Lindhal et al., 1986 in Lane D. and Lindahl U. (Eds.) "Heparin-Chemical and Biological Properties; Clinical Applications", Edward Arnold, London, pp. 159-190 and Lindahl U. Feingold D.S. and Rodén L., (1986) TIBS, 11, 221-225.

Fundamental for the heparin activity is the sequence consisting of the pentasaccharide region bonding for the antithrombin III (ATIII), called active pentasaccharide, which is the structure needed for the high affinity bond of heparin for ATIII. This sequence contains the only unit of glucosamine sulfated in position 3, which is not present in the other parts of the heparin chain. Beside the activity through ATIII, heparin exerts the anticoagulant and antithrombotic activity

activating the heparin cofactor II (HCII) with a subsequent selective inhibition of thrombin. It is known that the minimum saccharide sequence needed to activate HCII is a chain containing at least 24 monosaccharides (Tollefsen D.M., Seminars in Thrombosis and Hemostasis 16, 66-70 (1990)).

From previous studies it is known that the K5 capsular polysaccharide isolated from the Escherichia Coli strain described by Vann W.F., Schmidt M.A., Jann B., Jann K. (1981) in Eur. J. Biochem 116, 359-364 shows the same sequence of the precursor of heparin and heparan sulfate (N-acetyl heparosan). This compound has been chemically modified as described by Lormeau et al. in the US patent no. 5,550,116 and by Casu et al. (Carb. Res 263-1994-271-284) or chemically and enzymatically as described by Jann et al. (WO 92/17509) and by Casu et al., Carb. Letters 1, 107-114 (1994). These modifications result in products having biological activities in the in vitro tests about coagulation that however are not at the level of heparin from extraction from animal organs.

### SUMMARY

We have found new glycosaminoglycans derived from the K5 polysaccharide from Escherichia coli, having molecular weight from 2,000 to 30,000, containing from 25 to 50% by weight of the chains having high affinity for ATIII and having a high anticoagulant and antithrombotic activity which expressed as a ratio between the HCII/antiXa activities, lies in the range from 1.5 to 4, with a prevalence of the activities implicating the inhibition of thrombin.

Said glycosaminoglycans are prepared by a process comprising several steps of chemical and enzymatic treatment and characterized by a D-glucuronic acid to L-iduronic acid epimerization step using the glucuronosyl C-5 epimerase enzyme in solution or in immobilized form in presence of specific divalent cations, said enzyme being selected from the group consisting of recombinant glucuronosyl C-5 epimerase, glucuronosyl C-5 epimerase from murine mastocytoma and glucuronosyl C-5 epimerase from extraction from cattle-liver and said divalent cations being selected from the group consisting of Ba, Ca, Mg and Mn.

### DETAILED DESCRIPTION OF THE INVENTION

The present invention refers to the glycosaminoglycans derived from the K5

polysaccharide from *Escherichia coli* (below also simply called K5), obtained by a process comprising the following steps:

- a) Preparation of the K5 polysaccharide from *Escherichia coli*
- b) N-deacetylation/N-sulfation
- c) C-5 epimerization
- d) Supersulfation
- e) Selective O-desulfation
- f) (Optional) selective 6-O-sulfation
- g) N-sulfation

The various steps of the process are described in detail as follows.

- a) Preparation of the K5 polysaccharide from *Escherichia coli*

A fermentation in an Erlenmeyer flask is first carried out according to the MI99A001465 patent and using the following medium:

Degreased soy flour	2 gr/l
K <sub>2</sub> HPO <sub>4</sub>	9.7 gr/l
KH <sub>2</sub> PO <sub>4</sub>	2 gr/l
MgCl <sub>2</sub>	0.11 gr/l
Sodium citrate	0.5 gr/l
Ammonium sulfate	1 gr/l
Glucose	2 gr/l
Spring water	1,000 ml

pH = 7.3

The medium is sterilized at 120 °C for 20 minutes.

The glucose is separately prepared in form of solution which is sterilized at 120 °C for 30 minutes and added to the medium in a sterile way.

The Erlenmeyer flask is inoculated with a suspension of *E. coli* Bi 8337/41 cells (O10:K5:H4) coming from a slant kept in Tryptic soy agar, and incubated at 37 °C for 24 hours under controlled stirring (160 rpm, 6 cm run). The bacterial growth is measured counting the cells with the microscope.

In a subsequent operation, a 14 l Chemap-Braun fermenter containing the same previously mentioned medium, is inoculated at 0.1% with the culture of the above

Erlenmeyer flask and the fermentation is carried out by aeration of 1 vvm, (vvm = air volume per liquid volume per minute), 400 rpm stirring and 37 °C temperature for 18 hours. During the fermentation pH, oxygen, the residual glucose, the produced K5 polysaccharide and the bacterial growth are measured.

At the end of the fermentation the temperature is taken to 80 °C for 10 minutes. The cells are separated from the medium by 10,000 rpm centrifugation and the supernatant is ultrafiltered using a SS 316 module (MST) provided with PES membranes having 800 and 10,000 D nominal cut-off to reduce the volume to 1/5. The K5 polysaccharide is then precipitated by addition of 4 volumes of acetone at 4 °C and allowed to sedimentate overnight at 4 °C, and finally it is recovered by 10,000 rpm centrifugation for 20 minutes or filtration.

Then the deproteinization of the obtained solid is carried out using a type II protease from *Aspergillus Orizae* in 0.1 M NaCl buffer and 0.15 M EDTA at pH 8 containing 0.5% SDS (10 mg/l filtrate) at 37 °C for 90 minutes.

The obtained solution is ultrafiltered on SS 316 module with membranes having 10,000 D nominal cut-off with 2 extractions with 1M NaCl and washed with water to absorbance disappearance in the ultrafiltrate. The K5 polysaccharide is then precipitated with acetone and a 850 mg per liter of fermenter yield is obtained. The purity of the obtained polysaccharide is measured by the determination of the uronic acids (carbazole method), proton and carbon 13 NMR, UV and protein content. Purity turns out to be greater than 80%.

The obtained polysaccharide consists of two fractions having different average molecular weight, 30,000 and 5,000 D respectively as it results from the HPLC determination with two Bio-sil SEC 250 (Bio Rad) series columns and Na<sub>2</sub>SO<sub>4</sub> as mobile phase at room temperature and 0.5 ml/minute flux. The measure is carried out against a standard curve obtained with known molecular weight heparin fractions.

Triton X-100 is added to a 1% aqueous solution of the purified K5 polysaccharide until the achievement of a 5% solution. It is left for 2 hours at 55 °C under stirring. The temperature is increased to 75 °C and during the subsequent cooling at room temperature two phases are formed.

On the upper phase (organic phase) the thermal treatment is repeated with formation of the two phases, for other two times. The aqueous phase containing the polysaccharide is finally concentrated under reduced pressure and precipitated with acetone or ethanol. The organic phase is discarded. The sample purity is controlled by proton NMR and turns out to be 95%.

The yield of this treatment turns out to be 90%.

b) N-deacetylation/N-sulfation

10 g of purified K5 polysaccharide are solubilized in 100-2,000 ml of 2N sodium hydroxide and left to react at 40-80 °C for the time needed for the complete deacetylation, which is never greater than 30 hours. The solution is taken to room temperature and to neutral pH with 6N hydrochloric acid.

The solution containing the deacetylated K5 is maintained at 20-65 °C and added with 10-40 g of sodium carbonate with single addition and with 10-40 g of a sulfating agent selected among the available reagents such as the pyridine-sulfotrioxide adduct, trimethylamine-sulfotrioxide etc.

The addition of the sulfating agent is carried out in a variable time to 12 hours. At the end of the reaction, if necessary, the solution is taken to room temperature, then to pH 7.5-8 with a 5% hydrochloric acid solution.

The product is purified from the salts by known techniques such as for example by diafiltration using a 1,000 D spiral membrane (prepscale cartridge-Millipore). The process is ended when the permeate conductivity is lower than 1,000  $\mu$ S, preferably lower than 100  $\mu$ S. The obtained product is reduced in volume until the achievement of a 10% polysaccharide concentration using the same filtering system in concentration. The concentrated solution, if necessary, is dried by common methodologies.

The N-sulfate/N-acetyl ratio turns out to be from 10/0 to 7/3 measured by carbon 13 NMR.

c) C-5 epimerization:

The C-5 epimerization step according to the present invention may be carried out by glucuronyl C-5 epimerase enzyme (also simply called C-5 epimerase) in solution or in immobilized form.

- C-5 epimerization with in solution enzyme

From  $1.2 \times 10^7$  to  $1.2 \times 10^{11}$  cpm (counts per minute) of natural or recombinant C-5 epimerase enzyme, computed according to the method described by Campbell P. et al., Analytical Biochemistry 131, 146-152 (1983), are dissolved in 2-2,000 ml of 25 mM Hepes buffer at a pH from 5.5 to 7.4, containing 0.001-10 g of N-deacetylated N-sulfated K5, and one or more ions selected among barium, calcium, magnesium, manganese at a concentration between 10 and 60 mM. The reaction is carried out at a temperature between 30 and 40 °C, preferably 37 °C, for 1-24 hours. At the end of the reaction the enzyme is inactivated at 100 °C for 10 minutes.

The product is purified by passage on DEAE resin or DEAE Sartobind cartridge and removed by 2M NaCl and finally desalted on Sephadex G-10 resin or it is purified by precipitation with 2 ethanol volumes and passage on IR 120 H<sup>+</sup> resin to retransform it in sodium salt.

A product having an iduronic acid/glucuronic acid ratio ranging from 40:60 to 60:40 computed by <sup>1</sup>H-NMR as already described in the WO96/14425 patent is obtained.

- C-5 epimerization with immobilized enzyme

The C-5 epimerase enzyme, natural or recombinant, may be immobilized on various inert supports which may be resins or membranes or glass beads derivatized with reactive functional groups using the common bond techniques for the enzymes for example by cyanogen bromide, by glutaraldehyde, by carbodiimide or by reacting the enzyme with a ionic exchange resin or making it to be adsorbed on a membrane. According to the present invention, the attack reactions of the enzyme to the inert support are carried out in the presence of the N-deacetylated N-sulfated K5 substrate in order to avoid that the bond occurs through the active site of the enzyme with subsequent activity loss.

The measurement of the immobilized enzyme activity is carried out by recirculating through a column containing the immobilized enzyme the amount of N-deacetylated N-sulfated K5 theoretically convertible by the cpm of immobilized enzyme, dissolved in 25 mM Hepes buffer, 0.1 M KCl, 0.01% Triton X100 and

0.15 M EDTA at pH 7.4 at 37 °C overnight with 0.5 ml/minute flux. After the purification by DEAE chromatographic system and desalting on Sephadex G-10 the product is freeze-dried and tested for the iduronic acid content by the proton NMR technique.

The iduronic acid/glucuronic acid ratio must be about 30:70.

20-1,000 ml of a 25 mM Hepes solution at pH between 6 and 7.4 containing one or more ions selected among barium, calcium, magnesium, manganese in a concentration ranging from 10 to 60 mM and 0.001-10 g of N-deacetylated N-sulfated K5, thermostated at a temperature between 30 and 40 °C, are recirculated at a 30-160 ml/h flux for a time ranging from 1 to 24 hours in a column containing from  $1.2 \times 10^7$  to  $3 \times 10^{11}$  cpm equivalents of the immobilized enzyme on the inert support thermostated at a temperature ranging from 30 to 40 °C. At the end of the reaction the sample is purified by the same procedures pointed out in the epimerization in solution.

The obtained product exhibits a ratio between iduronic acid and glucuronic acid ranging from 40:60 to 60:40.

#### d) Supersulfation

The solution containing the epimerized product of the step c) at a 10% concentration is cooled to 10 °C and then passed through IR-120 H<sup>+</sup> cationic exchange resin or equivalent (35-100 ml). Both the column and the container of the eluate are maintained at 10 °C. After the passage of the solution the resin is washed with deionized water until the permeate pH is greater than 6 (about 3 volumes of deionized water). The acid solution is taken to neutrality with a tertiary or quaternary amine such as for example tetrabutylammonium hydroxide (15% aqueous solution) obtaining the relative ammonium salt. The solution is concentrated at minimum volume and freeze-dried. The obtained product is suspended in 20-500 ml of DMF or DMSO and added with 15-300 g of a sulfating agent such as the pyridine -SO<sub>3</sub> adduct in solid form or in a solution of DMF or DMSO. The solution is maintained at 20-70 °C, preferably between 40-60 °C for 2-24 hours.

At the end of the reaction the solution is cooled to room temperature and added



with acetone saturated with sodium chloride to the complete precipitation.

The precipitate is separated from the solvent by filtration, solubilized with the minimum amount of deionized water (for example 100 ml) and added with sodium chloride until the achievement of a 0.2 M solution. The solution is taken to pH 7.5-8 with 2N sodium hydroxide and added with acetone until complete precipitation. The precipitate is separated from the solvent by filtration. The obtained solid is solubilized with 100 ml of deionized water and purified from the residual salts by ultrafiltration as described in step b).

An aliquot is freeze-dried for the structural analysis of the supersulfated product by  $^{13}\text{C}$ -NMR.

The obtained product turns out to have a sulphates per disaccharide content equal to 2.0-3.5 computed according to Casu et al., Carbohydr. Res. Vol. 39, pp 168-176 (1975). The position 6 of the aminosugar is 80-95% sulfated and the position 2 is fully not sulfated. The other sulfate groups are present in the position 3 of the aminosugar and 2 and 3 of the uronic acid.

#### e) Selective O-desulfation

The solution containing the product obtained from step d) is passed through IR-120  $\text{H}^+$  cationic exchange or equivalent (35-100 ml). After the passage of the solution the resin is washed with deionized water until the pH of the permeate is greater than 6 (about 3 volumes of deionized water). The acid solution is taken to neutrality by pyridine addition. The solution is concentrated to minimum volume and freeze-dried. The obtained product is treated with 20-2,000 ml of a DMSO/methanol (9/1 V/V) solution and the obtained solution is kept at 45-90°C for 1-8 hours. At the end the solution is added with 10-200 ml of deionized water and then it is treated with acetone saturated with sodium chloride in an amount such as to complete the precipitation.

With the selective O-desulfation first the sulfate groups are removed from the position 6 of the aminosugar, then those ones of the positions 3 and 2 of the uronic acid and finally that one of the position 3 of the aminosugar.

The obtained solid is purified by diafiltration as described in step b).

An aliquot is freeze-dried for the structural analysis by  $^{13}\text{C}$ -NMR.

In case the NMR analysis reveals a content of sulphates in position 6 of the aminosugar greater than 60%, computed as described by Casu et al. *Arzneimittelforschung Drug Research* 33-1, 135-142 (1983) one goes directly to step g). Otherwise one goes on with the following step.

f) Selective 6-O-sulfation (optional)

The solution containing the product of the step e) is treated as described in step d) to obtain the tertiary or quaternary salt, operating however at 20-25 °C.

The ammonium salt is suspended in 20-500 ml of DMF. The suspension is cooled to 0 °C and treated with an amount of a sulfating agent such as the pyridine-SO<sub>3</sub> adduct computed as a function of the percentage of sulfate in position 6 of the aminosugar to be restored considering a minimum of 60% of 6-O sulfate computed as described above. Such an amount of sulfating agent is between two and ten equivalents with respect to the hydroxyl functions to sulfate. The sulfating agent is added by single addition or with subsequent additions in a maximum total time of 20 minutes.

The sulfating agent may be in powder or dissolved in a little amount of DMF.

The solution is kept to 0-5 °C for 0.5-3 hours. The solution is then treated with acetone saturated with sodium chloride in amounts such to complete the precipitation.

The obtained solid is purified by diafiltration as described in step b).

An aliquot is freeze-dried for the structural analysis by <sup>13</sup>C-NMR.

In case the 6-O-sulfate content is lower than 60% as measured by NMR technique, the step f) is repeated.

g) N-sulfation

The solution coming from the step f) or, possibly, from step e) is treated as described in step b) for the N-sulfation.

The glycosaminoglycans obtained by the process of the invention are characterized by proton and carbon 13 NMR and by biological tests such as antiXa, APTT, HCII, Anti IIa and affinity for ATIII.

The obtained product may be submitted to fractioning by column chromatographic technique or by ultrafiltration obtaining fractions having low molecular weight from

2,000 to 8,000 D and high molecular weight from 25,000 to 30,000 D or the product may be submitted to depolymerization controlled by known techniques such as for example the deamination with nitrous acid as described in WO8203627.

The typical characteristics concerning the biological activity of the glycosaminoglycans obtained by the process of the invention (IN-2018 UF and IN-2018 LMW) are reported in Table 1, in comparison with Heparin UF (4<sup>th</sup> int. Standard) and LMW Heparin (1<sup>st</sup> int. Standard).

Table 1

Biological Activity of the product obtained by the described process:

	Sample	UF Heparin (4 <sup>th</sup> int. Standard)	LMW Heparin (1 <sup>st</sup> int. Standard)	IN-2018 UF	IN-2018 LMW
1	Anti Xa	100	84	70-250	40-100
2	APTT	100	30	40-90	25-80
3	HCII	100	n.d.	300-500	100-200
4	Anti IIa	100	33	100-600	20-210
5	Average molecular weight	13500	4500	18000- 30000	4000-8000
6	ATIII Affinity	32%	n.d.	25-50	20-40

## REFERENCES

1. Thomas D.P. et al., Thrombosis and Haemostasis 45, 214-(1981) against the IV heparin international standard.
2. Andersson et al., Thrombosis Res. 9, 575 (1976) against the IV heparin international standard.
3. The test is carried out mixing 20 ml of HCII (Stago) 0.05 PEU/ml dissolved in water with 80  $\mu$ l of a solution of the sample under examination at different concentrations and 50  $\mu$ l of thrombin (0.18 U/ml- Boehringer) in 0.02 M tris buffer,

pH 7.4, containing 0.15 M NaCl and 0.1% PEG-6000. The solution is incubated for 60 sec. at 37 °C, then 50 µl of 1 mM Spectrozyme (American Diagnostic) chromogenic substrate are added. The reaction is recorded in continuum for 180 sec. with readings every second at 405 nm using a ACL-7000 (IL) automatic coagulometer.

4. The test is carried out mixing 30 µl of a 0.5 U/ml ATIII (Chromogenix) solution dissolved in 0.1 M tris buffer, pH 7.4, with 30 µl of a solution of the sample under examination at different concentrations and 60 µl of thrombin (5.3 nKat/ml-Chromogenix) in 0.1 M pH 7.4 tris buffer. The solution is incubated for 70 sec. at 37 °C, then 60 µl of 0.5 mM S-2238 (Chromogenix) chromogenic substrate in water are added. The reaction is recorded in continuum for 90 sec. with readings each second at 405 nm using a ACL-7000 (IL) automatic coagulometer.

5. Harenberg and De Vries, J. Chromatography 261, 287-292 (1983)

6. Hook M. et al. FEBS Letters 66, 90-93 (1976).

From the Table it is pointed out that the product obtained with the present process shows an activity comparable with the extractive heparin in the test referred to the Xa (1) factor and reduced the global (2) anticoagulant activity while the values of the test referring to the inhibition of thrombin (3, 4) turn out to be significantly greater. These characteristics configure in the obtained product greater antithrombotic properties and less side effects such as the bleeding effect with respect to the extractive heparin.

Thanks to their characteristics, the glycosaminoglycans according to the present invention may be used, alone or in form of combinations with pharmaceutically acceptable excipients or diluents, for the anticoagulant and antithrombotic treatment.

Therefore the present invention also includes the compositions containing an effective amount of said glycosaminoglycans in combination with pharmaceutically acceptable excipients or diluents.

Finally the present invention also refers to a therapeutic method including the administration of an effective amount of said glycosaminoglycans for the anticoagulant and antithrombotic treatment.

The following Examples are reported for illustrative aim of the invention.

#### EXAMPLE 1

The Example 1 is carried out according to the following steps:

a) 10 g. of the K5 polysaccharide obtained by fermentation as described in the MI99A001465 patent having 80% purity (Fig. 2) are dissolved in deionized water in order to obtain a 1% solution. Triton X-100 is added to obtain a 5% solution and the solution is kept for 2 hours at 55 °C under stirring.

The solution is heated to 75 °C and kept at this temperature until the formation of an homogeneous turbid system and then the solution is quickly cooled to room temperature.

In the cooling two phases are formed.

On the upper phase (organic phase) said thermal treatment is repeated for other two times. The aqueous phase containing the K5 polysaccharide is finally concentrated to 1/10 of the volume under reduced pressure and precipitated with acetone or ethanol.

The organic phase is discarded.

The recovered product consists of 90% purity K5 polysaccharide, controlled by proton NMR (Fig. 3) with respect to the spectrum of the internal standard (Fig. 1).

b) The product obtained from step a) is solubilized with 1,000 ml of 2N sodium hydroxide and left at 60 °C for 18 hours. The solution is taken to room temperature and then to neutral pH with 6N hydrochloric acid. One thus obtains the N-deacetylated K5 polysaccharide.

The solution containing the N-deacetylated K5 is maintained at 40 °C and added with 10 g of sodium carbonate with single addition and 10 g. of pyridine-sulfotrioxide adduct in 10 minutes. At the end of the reaction, the solution is taken to room temperature, then to pH 7.5-8 with a 5% hydrochloric acid solution.

The obtained product, consisting of the N-deacetylated N-sulfated K5 polysaccharide, is purified from the salts by diafiltration using a 1,000 D (prepscale cartridge-Millipore) spiral membrane. The purification process is ended when the permeate conductivity is lower than 100  $\mu$ S.

The product kept by the membrane is taken to a 10% polysaccharide

concentration using the same diafiltration system and then it is freeze-dried.

The N-sulfate/N-acetyl ratio in the obtained product turns out to be 9.5/0.5, measured by carbon 13 NMR (Fig. 4).

#### c) 1-Preparation of the immobilized C-5 epimerase enzyme

To 5 mg of recombinant C-5 epimerase obtained according to the WO98/48006 patent corresponding to  $1.2 \times 10^{11}$  cpm (counts per minute) dissolved in 200 ml of 0.25 M Hepes buffer, pH 7.4, containing 0.1 M KCl, 0.1% Triton X-100 and 15 mM EDTA, 100 mg of N-deacetylated N-sulfated K5 are added obtained as described in step b). The solution is diafiltered in a 30,000 D membrane at 4 °C until the disappearance of the N-deacetylated N-sulfated K5 in the diafiltered. To the solution kept by the membrane is then changed the buffer by diafiltration substituting it with 200 mM  $\text{NaHCO}_3$  at pH 7 and, after concentration at 50 ml, 50 ml of CNBr Sepharose 4b activated resin are added and it is left to react overnight at 4 °C.

At the end of the reaction the amount of residual enzyme in the supernatant is measured by the Quantigold (Diversified Biotec) method after centrifugation. The enzyme in the supernatant turns out to be absent, showing that with the described method the enzyme is 100% immobilized. In order to occupy the sites of the resin remained available the resin is washed with 100 mM TRIS-HCl buffer at pH 8.

For the measurement of the activity of the immobilized enzyme, an amount of immobilized enzyme theoretically corresponding to  $1.2 \times 10^7$  cpm, is loaded into a column. In the so prepared column 1 mg of N-deacetylated N-sulfated K5 obtained as described in step b) dissolved in 25 mM Hepes buffer, 0.1 M KCl, 0.015 M EDTA, 0.01% Triton X-100, at pH 7.4, is treated making it to recirculate through said column at 37 °C overnight with a 0.5 ml/minute flux.

After the purification by DEAE chromatographic system and desalting on Sephadex G10 the sample is freeze-dried and tested for the iduronic acid content by proton NMR technique as already described in the WO96/14425 patent.

The iduronic acid/glucuronic acid ratio is 30/70. (Fig. 5).

#### 2-Epimerization

10 g of the N-deacetylated N-sulfated K5 polysaccharide are dissolved in 600 ml of

25 mM HEPES buffer, pH 6.5, containing 50 mM  $\text{CaCl}_2$ . The obtained solution is made to recirculate through a 50 ml column loaded with the resin containing the immobilized enzyme.

This operation is carried out at 37 °C with a 200 ml/h flux for 24 hours.

The obtained product is purified by ultrafiltration and precipitation with ethanol.

The precipitate is resolubilized in water at a 10% concentration.

One obtains an epimerized product with a iduronic acid/glucuronic acid ratio equal to 48/52 against a 0/100 ratio of the starting product.

The epimerization percentage has been computed with  $^1\text{H-NMR}$  (Fig. 6).

The yield, computed measuring the uronic acids content against standard by the carbazole method (Bitter and Muir Anal. Biochem. 39, 88-92-1971) is equal to 90%.

d) The solution containing the epimerized product with 10% concentration coming from the step c) is taken to 10 °C with cooled bath and then it is passed on IR-120  $\text{H}^+$  (50 ml) cationic exchange resin. Both the column and the eluate container are kept at 10 °C. After the passage of the solution the resin is washed with 3 volumes of deionized water. The permeate pH turns out to be greater than 6. The acid solution is taken to neutrality with a 15% tetrabutylammonium hydroxide aqueous solution. The resulting solution is concentrated at 1/10 of the volume in a rotating evaporator at 40 °C under vacuum, and freeze-dried.

The product is suspended in 200 ml of DMF and added with 150 g of the pyridine- $\text{SO}_3$  adduct dissolved in 200 ml of DMF. The solution is kept at 45 °C for 18 hours. At the end of the reaction the solution is cooled to room temperature and added with 1,200 ml of acetone saturated with sodium chloride.

The obtained precipitate is separated from the solvent by filtration, solubilized with 100 ml of deionized water and added with sodium chloride until the achievement of a 0.2 M solution. The solution is taken to pH 7.5-8 with 2 N sodium hydroxide and added with 300 ml of acetone. The precipitate is separated by filtration. The obtained solid is solubilized with 100 ml of deionized water and purified from the residual salts by diafiltration as described in step b).

The  $^{13}\text{C-NMR}$  analysis on a freeze-dried aliquot of the supersulfated product is

shown in Fig. 7.

e) The solution containing the product of the step d) is passed on IR-120 H<sup>+</sup> (50 ml) cationic exchange resin. After the passage of the solution the resin is washed with 3 volumes of deionized water. The permeate pH turns out to be greater than 6. The acid solution is taken to neutrality with pyridine. The resulting solution is concentrated to 1/10 of the volume in a rotating evaporator at 40 °C under vacuum, and freeze-dried.

The obtained product, in form of pyridine salt, is added with 500 ml of a DMSO/methanol (9/1 V/V) solution. The solution is kept at 60 °C for 3.5 hours and then it is added with 50 ml of deionized water and finally it is treated with 1,650 ml of acetone saturated with sodium chloride.

The obtained solid is purified by diafiltration as described in the step b) obtaining a solution with 10% concentration.

The <sup>13</sup>C-NMR analysis on a freeze-dried aliquot is reported in Fig. 8 and it shows a sulfates in position 6 content of the aminosugar equal to 35%.

f) The solution containing the product of the step e) is passed on IR-120 H<sup>+</sup> (50 ml) cationic exchange resin. After the passage of the solution the resin is washed with 3 volumes of deionized water. The permeate pH turns out to be greater than 6. The acid solution is taken to neutrality with a 15% tetrabutylammonium hydroxide aqueous solution. The resulting solution is concentrated to 1/10 of the volume in a rotating evaporator at 40 °C under vacuum, and freeze-dried.

The product, in form of tetrabutylammonium salt, is suspended in 200 ml of DMF. The suspension is cooled to 0 °C and treated with 40 g of the pyridine-SO<sub>3</sub> adduct dissolved in 100 ml of DMF. The sulfating agent is added by single addition.

The solution is left at 0 °C for 1.5 hours and then it is treated with 750 ml of acetone saturated with sodium chloride.

The obtained solid is purified by diafiltration as described in the step b).

g) The solution coming from the step f) is treated as described in the step b) for the N-sulfation.

The <sup>13</sup>C-NMR analysis on a freeze-dried aliquot of the obtained product is shown in Fig. 9.



The obtained product shows the chemico-physical and biological characteristics reported in Table 2 - row 3 compared with the IV heparin international standard and with the I low molecular weight heparin international standard.

#### EXAMPLE 2

The Example 1 has been repeated with the difference that in the step c) the immobilized C-5 epimerase enzyme has been used extracted from murine mastocytoma as described by Jacobsson et al., J. Biol. Chem. 254, 2975-2982 (1979), with a reaction buffer containing 40 mM  $\text{CaCl}_2$ , pH 7.4.

The obtained product shows an iduronic acid/glucuronic acid ratio of 59.5 : 40.5 and the characteristics described in Table 2 row 4.

#### EXAMPLE 3

The Example 1 has been repeated with the difference that in the step c) the immobilized C-5 epimerase enzyme has been used extracted from cattle-liver as described in WO96/14425, with a reaction buffer at pH 7.4 and a reaction time equal to 32 hours. Moreover in the step e) the reaction time has been 4 hours.

The obtained product shows an iduronic acid/glucuronic acid ratio of 55.4 : 44.6 and the characteristics described in Table 2 row 5.

#### EXAMPLE 4

The Example 1 is repeated with the difference that in the step c) the recombinant C-5 epimerase enzyme in solution is used, using for the epimerization 10 g of N-deacetylated N-sulfated K5 dissolved in 1,000 ml of 25 mM HEPES buffer, pH 6.5, containing 50 mM  $\text{CaCl}_2$ . To this solution  $1.5 \times 10^{11}$  cpm equivalents of recombinant enzyme described in the Example 1 are added. The solution is kept at 37 °C for 24 hours. The solution is then treated at 100 °C for 10 minutes in order to denature the enzyme and finally it is filtered on 0.45  $\mu$  filter to obtain the clear solution containing the product. The obtained product is then purified by diafiltration and precipitation with ethanol or acetone. The precipitate is resolubilized in water at a concentration equal to 10% and treated as in the Example 1 keeping however the reaction time of the step e) for 2 hours.

The obtained product shows an iduronic acid/glucuronic acid ratio of 56 : 44 and the characteristics described in Table 2 row 6.

EXAMPLE 5

The Example 4 is repeated using in the step c) the enzyme from murine mastocytoma already described in the Example 2, in solution, with reaction buffer at pH 7.4 containing 40 mM  $\text{BaCl}_2$  and maintaining the reaction for 18 hours. Moreover in the step e) the reaction time is 3 hours. The obtained product shows an iduronic acid/glucuronic acid ratio of 40.1 : 59.9 and the characteristics described in Table 2 row 7.

EXAMPLE 6

The Example 4 is repeated using in the step c) the C-5 epimerase enzyme from cattle-liver already described in the Example 3, in solution with reaction buffer containing 12.5 mM  $\text{MnCl}_2$  and maintaining the reaction for 14 hours. Moreover in the step e) the reaction time is 4 hours. The obtained product shows a iduronic acid/glucuronic acid ratio of 44.3 : 55.7 and the characteristics described in Table 2 row 8.

EXAMPLE 7

The Example 4 is repeated using in the step c) a reaction buffer at pH 7.4 containing 37.5 mM  $\text{MgCl}_2$  and maintaining the reaction for 16 hours. Moreover in the step e) the reaction time is 4 hours.

The obtained product shows an iduronic acid/glucuronic acid ratio of 47.5 : 52.5 and the characteristics described in Table 2 row 9.

EXAMPLE 8

The Example 3 is repeated using in the step c) a reaction buffer at pH 7.0 containing 10 mM  $\text{MgCl}_2$ , 5 mM  $\text{CaCl}_2$ , 10 mM  $\text{MnCl}_2$  and maintaining the reaction for 24 hours. Moreover in the step e) the reaction time is 3 hours.

The obtained product shows an iduronic acid/glucuronic acid ratio of 44.8 : 55.2 and the characteristics described in Table 2 row 10.

EXAMPLE 9

The Example 6 is repeated using in the step c) a reaction buffer at pH 7.4 containing 10 mM  $\text{MgCl}_2$ , 5 mM  $\text{CaCl}_2$ , 10 mM  $\text{MnCl}_2$  and maintaining the reaction for 24 hours. Moreover in the step e) the reaction time is 3 hours.

The obtained product shows an iduronic acid/glucuronic acid ratio of 52 : 48 and

the characteristics described in Table 2 row 11.

#### EXAMPLE 10

The sample obtained in the Example 3 having a molecular weight distribution obtained according Harenberg and De Vries, J. Chromatography 261, 287-292 (1983) (Fig. 10) is submitted to separation by gel filtration technique. In particular 1 gram of product is dissolved in 20 ml of 1 M NaCl buffer solution and deposited on a column containing 1,000 ml of Sephacryl HR S-400 (Amersham-Pharmacia) resin. The column is then eluted with 2,000 ml of 1 M NaCl buffer solution and gathered in 50 ml equal fractions by fraction collector (Gilson). After the determination of the product content on each fraction by carbazole analysis (Bitter and Muir, Anal. Biochem. 39, 88-92-1971) the resulting fractions containing the sample are grouped in fraction A and fraction B respectively corresponding to the high molecular weight and low molecular weight portions. These fractions after concentration to 10 per cent of the volume by evaporator under vacuum are desalted in a column containing 500 ml of Sephadex G-10 (Amersham-Pharmacia) resin.

The solutions containing the desalted products are freeze-dried obtaining the fraction A and the fraction B (Fig. 11 A and Fig. 11 B). The obtained products show the characteristics described in Table 2 rows 12 and 13.

#### EXAMPLE 11

The sample obtained in the Example 4 is submitted to controlled degradation with nitrous acid as described in the WO 8203627 patent. In particular 5 g of sample are dissolved in 250 ml of water and taken to 4 °C with thermostated bath. The pH is taken to 2.0 with 1 N hydrochloric acid cooled to 4 °C and then 10 ml of a 1% sodium nitrite solution are quickly added. If necessary the pH is taken back to 2 with 1 N hydrochloric acid and it is kept under slow stirring for 15 minutes. The solution is neutralized with 1N NaOH cooled to 4 °C. Then 250 mg of sodium boron hydride dissolved in 13 ml of deionized water are added and it is left to react for 4 hours. It is taken to pH 5.0 with 1 N hydrochloric acid and it is left for 10 minutes in order to destroy the sodium boron hydride excess, and then it is neutralized with 1 N NaOH. The product is recovered by precipitation with 3

volumes of ethanol and then it is dried in vacuum stove. The obtained product shows the characteristics described in Table 2 row 14.

TABLE 2 - Anticoagulant and antithrombotic activity of the products obtained from the described Examples	1)Anti Xa (%)	2) APTT (%)	3) HCII (%)	4)Anti IIa (%)	5) MW	6) ATIII Affinity (%)
UF Heparin (4 <sup>th</sup> int. STD)	100	100	100	100	13500	32%
LMW Heparin (1 <sup>st</sup> int. Std)	84	30		33	4500	n.d.
Example 1	76.6	43.4	256	118	15200	29
Example 2	94.3	57	294	208	13500	29.5
Example 3	112	88	346	223	14600	28
Example 4	157	71.5	362	600	22500	29
Example 5	150	70	352	213	24000	31
Example 6	150	79	335	333	23000	33
Example 7	120	92	346	247	13000	29
Example 8	153	75	332	240	22500	34
Example 9	157	71	346	233	23000	35
Example 10-A	250	70.8	480	435	30000	48
Example 10-B	43	77.7	145	27.3	7600	24
Example 11	97.5	55.5	230	210	5400	25

The references from 1) to 6) have the meaning described for Table 1.

From the Table one points out that the product obtained with the present process

shows activities comparable with the extractive heparin in the tests relating to the Xa factor (1) while the global (2) anticoagulant activity is reduced and those tests referring to the inhibition of thrombin (3, 4) are significantly greater. These characteristics configure in the product greater antithrombotic properties and less side effects such as the bleeding effect with respect to the extractive heparin.

CLAIMS

1. N-deacetylated N-sulfated derivatives of the K5 polysaccharide, epimerized at least to 40% of L-iduronic acid with respect to the total of uronic acids, having molecular weight from 2,000 to 30,000 D, containing from 25 to 50% by weight of the chains having high affinity for ATIII and having an anticoagulant and antithrombotic activity expressed as HCII/antiXa ratio ranging from 1.5 to 4.
2. Derivatives as claimed in claim 1, characterized in that they have molecular weight ranging from 4,000 to 8,000 D.
3. Derivatives as claimed in claim 1, characterized in that they have molecular weight ranging from 18,000 to 30,000 D.
4. Process for the preparation of derivatives of the K5 polysaccharide as defined in claim 1, comprising in sequence the preparation of the K5 polysaccharide from Escherichia Coli, N-deacetylation and N-sulfation, C-5 epimerization of the D-glucuronic acid to L-iduronic acid, supersulfation, selective O-desulfation, selective 6-O-sulfation and N-sulfation, characterized in that said C-5 epimerization is carried out by the use of the glucuronosyl C-5 epimerase enzyme in solution or in immobilized form in presence of specific divalent cations.
5. Process as claimed in claim 4, characterized in that said enzyme is selected from the group consisting of recombinant glucuronosyl C-5 epimerase, glucuronosyl C-5 epimerase from murine mastocytoma and glucuronosyl C-5 epimerase from cattle-liver extraction.
6. Process as claimed in claim 4, characterized in that said divalent cations are selected from the group consisting of Ba, Ca, Mg and Mn and they are used individually or in combination among them.
7. Process as claimed in claims from 4 to 6, characterized in that said C-5 epimerization with the enzyme in solution is carried out by dissolution of an amount of the C-5 epimerase enzyme ranging from  $1.2 \times 10^7$  to  $1.2 \times 10^{11}$  cpm in 2-2,000 ml of 25 mM Hepes buffer at a pH from 5.5 to 7.4 containing from 0.001 to 10 g of N-deacetylated N-sulfated K5 and one or a combination of said cations at a concentration ranging from 10 to 60 mM.
8. Process as claimed in claim 7, characterized in that said C-5 epimerization with

the enzyme in solution is carried out at a temperature ranging from 30 to 40 °C for a time ranging from 1 to 24 hours.

9. Process as claimed in claims from 4 to 6, characterized in that said C-5 epimerization with the enzyme in immobilized form is carried out by recirculation of 20-1,000 ml of a 25 mM Hepes buffer solution at a pH from 6 to 7.4, containing 0.001-10 g of N-deacetylated N-sulfated K5 and one of said cations at a concentration ranging from 10 to 60 mM, through a column containing from  $1.2 \times 10^7$  to  $3 \times 10^{11}$  cpm of the enzyme immobilized on an inert support.

10. Process as claimed in claim 9, characterized in that said C-5 epimerization is carried out at a temperature from 30 to 40 °C making said solution to recirculate with a 30-160 ml/h flux for a time ranging from 1 to 24 hours.

1/12




FIG. 1



2/12




Fig. 2

3/12




Fig. 3

4/12




Fig. 4

5/12




Fig. 5




Fig. 6

7/12




Fig. 7

8/12




Fig. 8

9/12




Fig. 9



10/12




Fig. 10

11/12




Fig. 11A

12/12




Fig. 11B

## INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/EP 01/03461

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 C08B37/10 C08B37/00 A61K31/715

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 C08B A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, COMPENDEX, IBM-TDB, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 43317 A (CIPOLLETTI GIOVANNI ; PASQUA ORESTE (IT); INALCO SPA (IT); ZOPPETTI) 20 November 1997 (1997-11-20)	1-3
A	page 3, line 15,16; claim 1; example 4; table 2	4-10
X	WO 96 14425 A (INALCO SPA ; ZOPPETTI GIORGIO (IT); PASQUA ORESTE (IT); CIPOLLETTI) 17 May 1996 (1996-05-17) cited in the application	1-3
A	page 5, line 3,4; claim 1; examples 1-9	4-10
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

9 August 2001

Date of mailing of the international search report

20/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Radke, M

## INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/EP 93/03461

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CASU B ET AL: "Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5" CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 263, no. 2, 17 October 1994 (1994-10-17), pages 271-284, XP004022216 ISSN: 0008-6215 * Abstract; reaction scheme on page 273 * table 1 ---	1-10
A	WO 98 42754 A (TORRI GIANGIACOMO ;CASU BENITO (IT); INALCO SPA (IT); NAGGI ANNAMA) 1 October 1998 (1998-10-01) page 10, line 4-7; claims 1,7; examples 16,17 -----	1-10

INTERNATIONAL SEARCH REPORT  
Information on patent family members

International Application No

PCT/EP 01/03461

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9743317	A	20-11-1997	IT MI960956 A	10-11-1997
			AU 3026597 A	05-12-1997
			EP 0897393 A	24-02-1999
			US 6162797 A	19-12-2000
WO 9614425	A	17-05-1996	IT 1271057 B	26-05-1997
			AT 195348 T	15-08-2000
			AU 3926195 A	31-05-1996
			CA 2204366 A	17-05-1996
			DE 69518333 D	14-09-2000
			DE 69518333 T	22-02-2001
			DK 789777 T	06-11-2000
			EP 0789777 A	20-08-1997
			ES 2150589 T	01-12-2000
			JP 10508204 T	18-08-1998
			PT 789777 T	31-01-2001
			US 5958899 A	28-09-1999
WO 9842754	A	01-10-1998	IT MI970678 A	24-09-1998
			AU 7040598 A	20-10-1998
			EP 0970130 A	12-01-2000
			US 6197943 B	06-03-2001